NCT02109341View on ClinicalTrials.gov

Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

Paclitaxel bound albumine

Trial Locations (8)

26100

Azienda Ospedaliera Istituti Ospedalieri di Cremona, Cremona

37134

Ospedale Borgo Roma, Verona

42100

Arcispedale Santa Maria Nuova, Reggio Emilia

50134

SC Oncologia Medica 1, Florence

56126

Ospedale S. Chiara - Azienda Ospedaliero-Universitaria Pisana, Pisa

71013

IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo

82100

Ospedale Sacro cuore di Gesù - FATEBENEFRATELLI, Benevento

00144

Regina Elena National Cancer Institute, Rome

All Listed Sponsors
lead

Gruppo Oncologico Italiano di Ricerca Clinica

OTHER

NCT02109341 - Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter